论文部分内容阅读
目的:初步评价温胆颗粒对替诺福韦(TDF)药代动力学影响作用。方法:温胆颗粒治疗2周,留取治疗前后患者血浆标本,进行TDF药物药代动力学检测并进行分析。结果:温胆颗粒治疗前后TDF血浆药代动力学参数:AUC(0-t)疗前:(4 855.2±1 371.5)μg/L·h,疗后(4 761.1±1 889.6)μg/L·h;t1/2z疗前:(18.00±12.07)h,疗后(33.55±49.34)h;Tmax疗前:(3.45±3.12)h,疗后(1.75±1.03)h;Cmax疗前:(428.0±156.0)μg/L,疗后(516.7±206.8)μg/L,且上述药代动力学参数治疗前后均未见显著性差异。结论:温胆颗粒对血浆TDF药代动力学无显著影响作用。
Objective: To evaluate the effect of Wendan Granule on the pharmacokinetics of tenofovir (TDF). Methods: Wendan granule was treated for 2 weeks. The plasma samples of patients before and after treatment were collected and the pharmacokinetics of TDF were detected and analyzed. Results: The pharmacokinetic parameters of TDF before and after treatment of Wen Dan Granules were: AUC (0-t) before treatment: (4 855.2 ± 1 371.5) μg / L · h, after treatment (7621.1 ± 1 889.6) μg / L · h; t1 / 2z before treatment: (18.00 ± 12.07) h, after treatment (33.55 ± 49.34) h; Tmax before treatment: (3.45 ± 3.12) h, ± 156.0) μg / L, after treatment (516.7 ± 206.8) μg / L, and there was no significant difference between the above pharmacokinetic parameters before and after treatment. Conclusion: Wen Dan Granule has no significant effect on the pharmacokinetics of plasma TDF.